Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on October 29, 2020. The Company is a Nevada corporation with principal executive offices in Framingham, Massachusetts. Its common stock and purchase warrants trade on The NASDAQ Stock Market LLC under the symbols "XBIO" and "XBIOW," respectively.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a regulatory compliance matter regarding the Company's stock listing status.
Material Changes and Events
On October 29, 2020, the Company received a written notice from the Listing Qualifications Department of the NASDAQ Stock Market LLC. The notice stated that the closing bid price for the Company's common stock had been below $1.00 for 30 consecutive business days, resulting in non-compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement").
- Compliance Period: The Company has 180 calendar days from the date of the notice to regain compliance.
- Compliance Date: April 27, 2021.
- Requirement to Regain Compliance: The closing bid price must be at least $1.00 for a minimum of ten consecutive business days prior to the Compliance Date.
- Immediate Effect: The notice has no immediate effect on the listing of the Company's common stock.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price and may consider available options to regain compliance, including a reverse stock split if necessary. However, the Company explicitly states there can be no assurance that it will be able to regain compliance with the Bid Price Requirement or other Nasdaq Listing Rules.
If the Company fails to regain compliance by the Compliance Date, it may be eligible for an additional 180-day compliance period. To qualify for this second period, the Company must meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, excluding the Bid Price Requirement.
The filing includes standard forward-looking statements regarding risks such as general market factors, competitive product development, regulatory processes, and patent litigation, referencing the Company's 2019 Form 10-K for a detailed list of risk factors.
Key Facts for Investor Verification
- Verify the current closing bid price of XBIO to assess the likelihood of meeting the $1.00 threshold for ten consecutive days.
- Monitor the Company's announcements regarding potential reverse stock splits or other capital structure changes intended to cure the deficiency.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if the initial deadline is missed.
- Check for subsequent filings (e.g., 8-K or press releases) confirming the restoration of compliance or notification of delisting proceedings.